CSIMarket Company Name, Ticker, Suppliers, else..
 
Bolt Biotherapeutics Inc   (NASDAQ: BOLT)
 
Price: $3.9000 $0.01 0.128%
Day's High: $3.9999001026153564 Week Perf: -2.01 %
Day's Low: $ 3.85 30 Day Perf: 0.78 %
Volume (M): 9,481 52 Wk High: $ 7.20
Volume (M$): $ 0 52 Wk Avg: $4.88
Open: $3.90 52 Wk Low: $3.13



 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 2
 Employees 23
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -29
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

Business Description


Bolt Biotherapeutics Inc is a biotechnology company focused on developing immune-stimulating therapies for cancer treatment. The company's proprietary Immune-Stimulating Antibody Conjugates (ISACs) aim to enhance the body's immune response to specifically target and kill cancer cells. Bolt Biotherapeutics' therapies utilize a unique approach that combines the specificity of monoclonal antibodies with the ability to activate the immune system. By leveraging this technology, the company aims to provide more effective and durable treatments for patients with various types of cancer.


   Company Address: 900 Chesapeake Drive Redwood City 94063 CA
   Company Phone Number: 665-9295   Stock Exchange / Ticker: NASDAQ BOLT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        2.68% 
MRK        1.33% 
OGN        0.15% 
TEVA   -0.22%    
VRTX        0.82% 
VTRS        3.3% 
• View Complete Report
   



Clinical Study

Analysis of Phase 1 Dose-Escalation Clinical Study Results for BDC-3042 Presented at AACR Annual Meeting 2025

Published Fri, Apr 25 2025 6:00 PM UTC

: At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), Bolt Biotherapeutics unveiled promising results from their Phase 1 dose-escalation clinical trial of BDC-3042. This investigational therapy shows notable potential for oncological interventions, having demonstrated a positive safety profile and an absence of dose-limiting toxicities up to ...
Clinical Study

Advancements in Cancer Immunotherapy Insights from Bolt Biotherapeutics BDC-4182 and BDC-1001

Published Thu, Nov 7 2024 3:00 PM UTC

: Recent advancements in the realm of immunotherapy have showcased significant potential in battling cancer due to innovative approaches that harness the immune system. This article delves into the promising preclinical data for BDC-4182 presented by Bolt Biotherapeutics, alongside crucial findings from the Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeti...
Announcement

Navigating Legal Turbulence The Impact of Securities Class Action on Bolt Biotherapeutics,

Published Wed, Aug 14 2024 6:23 PM UTC

Navigating Legal Waters: The Bolt Biotherapeutics Securities Class Action and Its Implications In recent news, Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage immuno-oncology company, has found itself at the center of a securities class action lawsuit. The Rosen Law Firm, known for its expertise in investor rights, has actively encouraged investors who purchased ...
Announcement

Bolt Biotherapeutics Faces Investor Investigation by Pomerantz Law Firm: Is Trouble Brewing for the Company

Published Wed, Jun 5 2024 7:26 PM UTC




New York-based law firm, Pomerantz LLP, has initiated an investigation into the claims made by investors of Bolt Biotherapeutics, Inc. (Bolt or the Company) (NASDAQ: BOLT). With rising concerns over potential misconduct or viol...
Clinical Study

Bolt Biotherapeutics Enters Phase 2 Trial with BDC-1001, Potentially Revolutionizing HER2-Positive Breast Cancer Treatment, Amidst Revenue Growth

Published Tue, Dec 5 2023 12:00 PM UTC


Bolt Biotherapeutics Initiates Phase 2 Study for BDC-1001 in HER2-Positive Breast Cancer Patients Previously Treated with Enhertu
REDWOOD CITY, Calif., Dec. 05, 2023 - Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a leading biopharmaceutical company specializing in novel immunotherapies for cancer treatment, has announced the enrollment of the first patient in their Ph...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.40
Price to Sales (Expected) -
Price to Book 0.52
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.79
Working Capital Ratio 4.14
Leverage Ratio (MRQ) 2.19
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -16.15 $
Revenues (TTM) 2.78 $
Cash Flow (TTM) 1.89 $
Cash 17.64 $
Book Value 7.48 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 204,348
Net Income per Employee (TTM) -1,249,522
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.09

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -167480 %
Net Margin (MRQ) -154400 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Bolt Biotherapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.